Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 1999

View Archived Issues

Eisai product pipeline update

Milestone achieved in Warner-Lambert/Unigene collaboration for oral calcitonin product

ID Biomedical seeks U.S. marketing clearance for MRSA test

SomatoKine reduces insulin use, improves glycemic control in type I diabetes

Access to acquire Virologix

FDA issues complete response letter for Rebif BLA

Endorex updates cancer and drug delivery programs

Novel hypoglycemic compounds designed at RPR

Novel vitamin D compounds with favorable biological profile from WARF

Pfizer discloses novel macrolide antibiotics

PDE4 inhibitors claimed by Byk Gulden for airways disorders

Vitronectin receptor antagonists with a benzocycloheptene core designed at SB

Second Ligand/Wyeth-Ayerst SERM to enter clinical trials shortly

Janssen confirms lubeluzole no longer under development

SS Pharm. outlicenses drug candidates to speed development, reduce costs

Alertec approved in Canada for treatment of narcolepsy

Biochemical and pharmacological profile of new MAO-A inhibitor: 2614W94

Cubist Pharmaceuticals initiates pivotal clinical trials for daptomycin

Licensing opportunity from BTG: xanthine oxidase inhibitors for treatment of ARDS

Epothilone analogue markedly suppresses growth of or cures MDR tumors in vivo

RCT supports early-stage life science discoveries originating in New England

Vasoflux is superior to other anticoagulants due to its unique mechanism of action

HFA-134a-BDP controls asthma at half the dose of traditional inhalers

Gadophrin-2 in the assessment of infarct size in dogs

Preclinical results obtained with candidate antidiabetic support further testing

Nuvance advances to phase II clinical trials for long-term control of asthma

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026